The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer

Documenti analoghi

• Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
  di: Weili Xiong, et al.
  Pubblicazione: (2024)
• An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer
  di: Xinyu Wu, et al.
  Pubblicazione: (2025)
• Prognostic implications of HER2NEU‐low in metastatic breast cancer
  di: Zachary Neubauer, et al.
  Pubblicazione: (2024)
• Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
  di: Lan Chen, et al.
  Pubblicazione: (2024)
• The evolution and prognostic impact of HER2‐low, HER2‐ultralow, and HER2‐null status in HER2‐negative early breast cancer: A pre– to post–neoadjuvant chemotherapy study
  di: Yibin Qiu, et al.
  Pubblicazione: (2026)